Nanopharma - Company finances
|
EUR
|
2018
From: 2018-10-31
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 8,264 | 7,680 | - | - | - | - | - | - |
| Profit before tax | 7,274 | 1,015 | -3,045 | -590 | -167 | -356 | -83 | -84 |
| Net profit | 7,274 | 945 | -3,045 | -590 | -167 | -356 | -83 | -84 |
| Equity | 7,275 | 8,220 | 5,175 | 4,585 | 4,417 | 4,061 | 3,978 | 3,894 |
| Liabilities | - | - | - | - | 3,737 | 4,521 | 4,521 | 4,521 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current assets | 10,224 | 12,118 | 8,999 | 8,186 | 8,154 | 8,582 | 8,499 | 8,415 |
| Total assets | 10,224 | 12,118 | 8,999 | 8,186 | 8,154 | 8,582 | 8,499 | 8,415 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | -7.1% | - | - | - | - | - | - |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 71.1% | 7.8% | -33.8% | -7.2% | -2.0% | -4.1% | -1.0% | -1.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 100.0% | 11.5% | -58.8% | -12.9% | -3.8% | -8.8% | -2.1% | -2.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 88.0% | 12.3% | - | - | - | - | - | - |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 88.0% | 13.2% | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | 0.8 | 1.1 | 1.1 | 1.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Nanopharma - Social security debts
The company had no debts to Sodra
Nanopharma - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.